A Trial of Lu AH69593 in Healthy Participants
← catalyst calendarNCT07775261 · readout in 75 d
Sponsored by H. Lundbeck A/S (industry) · HLUN-B.CO — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
46estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-20
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-27 | estimated | When the study began enrolling |
| Primary completion | 2026-11-04 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-06 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: Lu AH69593
- Drug: Itraconazole
- Drug: Carbamazepine
- Drug: Midazolam
Primary outcomes
what the primary-completion date above is the date OFParts A and B: Area Under the Lu AH69593 Plasma-concentration-time Curve from Zero to Infinity (AUC0-inf)
measured Up to Day 13
Parts A and B: Maximum Observed Plasma Concentration (Cmax) of Lu AH69593
measured Up to Day 13
Part C: (AUC0-inf) of Midazolam
measured Up to Day 9
Part C: Cmax of Midazolam
measured Up to Day 9
Permalink · HLUN-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed